Navigation Links
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Date:5/8/2008

ARLINGTON HEIGHTS, Ill. Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). This new delivery technique, which has yet to be tested in humans, did not cause toxicity in the body of rats; however, administering the same anti-tumor agent intravenously in humans has previously been shown to cause liver damage.

This new technique may allow us to reprogram skin flaps, using gene therapy, to provide a blueprint for anti-tumor agents like Interleukin-12 to be produced in the tumor to kill cancer, while avoiding adverse side effects, said Geoffrey Gurtner, MD, ASPS Member and study senior author. In this study we took skin flaps in animal models and delivered IL-12 directly to the tumor area with tremendous success. Since skin flaps are used thousands of times each year in cancer patients, this may potentially open up an entirely new area in plastic surgery and bring the specialty, once again, to the center of medicine.

Gene therapy has been heralded as a new tool to restrain or prevent tumor growth and recurrence in humans, but its use has been limited because of serious side effects and the difficulty in concentrating anti-tumor agents at the site of the cancer.

In the study, skin flaps (a mass of healthy tissue) taken from rats were injected with the gene for IL-12 into the flaps blood supply. The flaps were then placed onto cancerous tumors on the rats.

The study found a 79 percent reduction in tumor volume for animals treated with IL-12 compared to control animals. The treatment allowed individual cells within the flap to become encoded with IL-12 and function as miniature factories producing the IL-12 protein at very high levels in the tumor site, according to the study.

Additionally, the serious side effects previously documented with systemic use of IL-12 were not found in the treated rats. The liver, lung and spleen remained normal throughout the study. The delivery technique through free flaps did not cause liver toxicity, whereas using IL-12 intravenously in humans has been shown to cause liver damage.

This could be a major advance for the delivery of a therapeutic agent to diseased parts of the body, said Dr. Gurtner. I can see this therapy being used for breast cancer, head and neck cancers, central nervous system malignancies, and somewhere down the line hemophilia, diabetes and infections.

The study authors concluded that as oncologic reconstructive surgery is a major component of plastic surgery, the delivery of a healing agent precisely to the region where cancer was and where local recurrences are most likely to occur, could add a new dimension to the reconstructive function of free flaps in oncologic and reconstructive plastic surgery.


'/>"/>

Contact: ASPS Media Relations
media@plasticsurgery.org
847-228-9900
American Society of Plastic Surgeons
Source:Eurekalert

Related medicine news :

1. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
2. KePROs Chief Medical Officer to Deliver Clinical Keynote Address
3. Doctors Discover Marker for Meconium Passage During Delivery
4. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
5. Mothers with Breast Cancer Can Dine to Thrive with Gourmet Meal Delivery
6. Medco Joins Cincinnatis Cover the Uninsured Week Effort To Deliver Lower Cost Health Care
7. SpongeTech(R) Delivery Systems, Inc. Clarification of Yesterdays $7,500,000 Order of Uncle Normans(TM) Pet Sponge
8. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
9. The Heritage Group Selects AccuNurse(R) to Improve Efficiency and Deliver Proactive Care
10. The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference
11. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
Breaking Medicine Technology: